Developing a Potential mRNA Influenza Vaccine

In September, Pfizer announced the start of a Phase 3 study of an mRNA-based influenza vaccine candidate that could potentially deliver an improved flu vaccine.

The disease causes 140,000 to 710,000 hospitalizations and 12,000 to 52,000 deaths in the U.S. every year. Since 2018, Pfizer has been working to develop a potential mRNA influenza vaccine, after entering into a collaboration agreement with BioNTech.

Pfizer is committed to continuing to advance mRNA technology to unlock its full potential for the benefit of patients around the world. The trial is a part of Pfizer’s broader influenza vaccine development program, focused on leveraging mRNA technology in a vaccine to help protect against influenza.

Learn more about this effort here.

Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.

Copyright © 2002 – 2022 Pfizer Investor Insights All rights reserved. This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries.

¹Disease Burden of Flu. CDC. Available at https://www.cdc.gov/flu/about/burden/index.html